BR0308221A - Derivados de tiazol e oxazol que modulam a atividade de ppar - Google Patents

Derivados de tiazol e oxazol que modulam a atividade de ppar

Info

Publication number
BR0308221A
BR0308221A BR0308221-0A BR0308221A BR0308221A BR 0308221 A BR0308221 A BR 0308221A BR 0308221 A BR0308221 A BR 0308221A BR 0308221 A BR0308221 A BR 0308221A
Authority
BR
Brazil
Prior art keywords
ppar activity
compounds
thiazole
oxazole derivatives
relates
Prior art date
Application number
BR0308221-0A
Other languages
English (en)
Inventor
Xue-Min Cheng
Noe Ouano Erasga
Gary Frederick Filzen
Andrew George Geyer
Chitase Lee
Bharat Kalidas Trivedi
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR0308221A publication Critical patent/BR0308221A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"DERIVADOS DE TIAZOL E OXAZOL QUE MODULAM A ATIVIDADE DE PPAR". A presente invenção refere-se a compostos que alteram a atividade de PPAR. A invenção também refere-se a sais farmaceuticamente aceitáveis de compostos, composições farmaceuticamente aceitáveis compreendendo os compostos ou seus sais, e métodos de empregá-los como agentes terapêuticos para tratamento ou prevenção de hiperlipidemia e hipercolesteremia em um mamífero. A presente invenção também refere-se a método para a preparação os compostos descritos.
BR0308221-0A 2002-03-07 2003-03-03 Derivados de tiazol e oxazol que modulam a atividade de ppar BR0308221A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36240002P 2002-03-07 2002-03-07
PCT/IB2003/000817 WO2003074052A1 (en) 2002-03-07 2003-03-03 Thiazole and oxazole derivatives that modulate ppar activity

Publications (1)

Publication Number Publication Date
BR0308221A true BR0308221A (pt) 2005-01-04

Family

ID=27789156

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308221-0A BR0308221A (pt) 2002-03-07 2003-03-03 Derivados de tiazol e oxazol que modulam a atividade de ppar

Country Status (29)

Country Link
US (1) US6833380B2 (pt)
EP (1) EP1485091A1 (pt)
JP (1) JP2005524665A (pt)
KR (1) KR20040091694A (pt)
CN (1) CN1638768A (pt)
AP (1) AP2004003123A0 (pt)
AR (1) AR038883A1 (pt)
AU (1) AU2003207891A1 (pt)
BR (1) BR0308221A (pt)
CA (1) CA2476580A1 (pt)
CO (1) CO5601013A2 (pt)
EA (1) EA200401160A1 (pt)
EC (1) ECSP045275A (pt)
GT (1) GT200300053A (pt)
HR (1) HRP20040810A2 (pt)
IL (1) IL163768A0 (pt)
IS (1) IS7399A (pt)
MA (1) MA27182A1 (pt)
MX (1) MXPA04008624A (pt)
NO (1) NO20044245L (pt)
OA (1) OA12781A (pt)
PA (1) PA8568701A1 (pt)
PE (1) PE20031010A1 (pt)
PL (1) PL372971A1 (pt)
TN (1) TNSN04167A1 (pt)
TW (1) TW200400027A (pt)
UY (1) UY27704A1 (pt)
WO (1) WO2003074052A1 (pt)
ZA (1) ZA200406491B (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867224B2 (en) * 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US20050203151A1 (en) * 2003-12-19 2005-09-15 Kalypsys, Inc. Novel compounds, compositions and uses thereof for treatment of metabolic disorders and related conditions
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
WO2005105726A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
WO2005115383A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of ppar and methods of their preparation
EP1749000A4 (en) * 2004-05-25 2009-12-30 Metabolex Inc BICYCLIC SUBSTITUTED TRIAZOLE AS PPAR MODULATORS AND METHOD FOR THE PRODUCTION THEREOF
AU2006265172B2 (en) 2005-06-30 2011-09-15 Vtv Therapeutics Llc Phenoxy acetic acids as PPAR delta activators
CN1896069B (zh) * 2005-07-15 2011-10-05 中国科学院上海药物研究所 一类取代噻唑-4酮化合物、制备方法和用途
EA201101085A1 (ru) 2005-12-22 2012-05-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
WO2007101864A2 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
AU2008297877C1 (en) 2007-09-14 2013-11-07 Addex Pharma S.A. 1,3-disubstituted-4-phenyl-1 H-pyridin-2-ones
MY152078A (en) 2007-09-14 2014-08-15 Ortho Mcneil Janssen Pharm 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
TW200922566A (en) 2007-09-14 2009-06-01 Ortho Mcneil Janssen Pharm 1,3 disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
CA2704436C (en) 2007-11-14 2016-01-05 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
US8691849B2 (en) 2008-09-02 2014-04-08 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
JP5656848B2 (ja) 2008-10-16 2015-01-21 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体モジュレーターとしてのインドールおよびベンゾモルホリンの誘導体
RU2512283C2 (ru) 2008-11-28 2014-04-10 Янссен Фармасьютикалз, Инк. Производные индола и бензоксазина в качестве модуляторов метаботропных глутаматных рецепторов
EA020671B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
PT2430022E (pt) 2009-05-12 2013-12-26 Janssen Pharmaceuticals Inc Derivados de 1,2,3-triazolo[4,3-a]piridina e a sua utilização para o tratamento ou prevenção de doenças neurológicas e psiquiátricas
US9012448B2 (en) 2010-11-08 2015-04-21 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
WO2015035171A1 (en) 2013-09-09 2015-03-12 High Point Pharmaceuticals, Llc Use of a ppar-delta agonist for treating muscle atrophy
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
CN113045523B (zh) * 2019-12-27 2022-09-23 上海泓博智源医药股份有限公司 一种咪唑啉吡啶化合物中间体的制备方法
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
ATE236137T1 (de) 1996-02-02 2003-04-15 Merck & Co Inc Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
EE03765B1 (et) 1996-08-19 2002-06-17 Japan Tobacco Inc. Propioonhappe derivaadid ja nende kasutamine
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
CA2418104A1 (en) 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
AU2001284658A1 (en) 2000-08-23 2002-03-13 Eli Lilly And Company Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031109D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
EP1345916A1 (en) 2000-12-20 2003-09-24 Glaxo Group Limited Substituted oxazoles and thiazoles as hppar alpha agonists
GB0111523D0 (en) 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
AU2002308891B2 (en) 2001-05-29 2007-09-06 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic derivatives and medicinal use thereof
KR20040030658A (ko) 2001-06-07 2004-04-09 일라이 릴리 앤드 캄파니 페록시좀 증식제 활성화 수용체의 조절제
EP1405848B1 (en) 2001-06-18 2008-05-07 Ono Pharmaceutical Co., Ltd. Tetrahydroquinoline derivative compound and drug containing the compound as active ingredient
AR036237A1 (es) 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
CN1585638A (zh) 2001-09-14 2005-02-23 图拉里克公司 被连接的联芳基化合物
US20030207924A1 (en) 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation

Also Published As

Publication number Publication date
AR038883A1 (es) 2005-02-02
PE20031010A1 (es) 2003-12-12
EP1485091A1 (en) 2004-12-15
KR20040091694A (ko) 2004-10-28
OA12781A (en) 2006-07-07
EA200401160A1 (ru) 2005-02-24
TNSN04167A1 (fr) 2007-03-12
UY27704A1 (es) 2003-10-31
CN1638768A (zh) 2005-07-13
PL372971A1 (en) 2005-08-08
HRP20040810A2 (en) 2004-12-31
PA8568701A1 (es) 2003-11-12
ECSP045275A (es) 2004-10-26
GT200300053A (es) 2003-10-10
MA27182A1 (fr) 2005-01-03
WO2003074052A1 (en) 2003-09-12
CA2476580A1 (en) 2003-09-12
AU2003207891A1 (en) 2003-09-16
CO5601013A2 (es) 2006-01-31
MXPA04008624A (es) 2004-12-06
ZA200406491B (en) 2006-05-31
IL163768A0 (en) 2005-12-18
US20030207916A1 (en) 2003-11-06
US6833380B2 (en) 2004-12-21
NO20044245L (no) 2004-10-06
TW200400027A (en) 2004-01-01
IS7399A (is) 2004-08-12
AP2004003123A0 (en) 2004-09-30
JP2005524665A (ja) 2005-08-18

Similar Documents

Publication Publication Date Title
BR0308221A (pt) Derivados de tiazol e oxazol que modulam a atividade de ppar
BR0308277A (pt) Derivados tiazol e oxazol que modulam a atividade de ppar
BR0308202A (pt) Tiazóis e oxazóis substituìdos que modulam a atividade de ppar
BR0309169A (pt) Compostos que modulam a atividade ppar e métodos para a sua preparação
BRPI0409486A (pt) compostos que modulam atividade de ppar e métodos para a sua preparação
BR112021020372A2 (pt) Métodos de tratamento de linfoma não hodgkin ao usar 2-(2,6-dioxopiperidin-3-il)-4-((2-fluo ro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)isoin dolina-1,3-diona
DK2316831T3 (da) 2-(Morpholin-4-yl)pyrimidiner som phosphotidylinositol (PI)-3-kinaseinhibitorer samt deres anvendelse ved behandling af cancer
BRPI0718714B8 (pt) arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende
BRPI0510095A (pt) tiazol substituìdo e derivados de pirimidina como moduladores de receptores de melanocortina
BR0112476A (pt) Uso de agonistas do receptor d2/d3 de dopamina para tratar fibromialgia
BR0109703A (pt) Derivados de piperazina
BR0013493A (pt) Agente promotor de produção/secreção de neurotrofina, derivado de tiazol, prodroga, composto, composição farmacêutica, derivado de oxazol, cristal, métodos para promover produção/secreção de neurotrofina em um mamìfero necessitando do mesmo e para prevenir ou tratar neuropatia em um mamìfero necessitando do mesmo, e, usos de um derivado de azol, de tiazol e de oxazol
BRPI0518222A (pt) composto, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3 e utilização dos mesmos
BRPI0513565A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
BRPI0615158A8 (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição, e para preparar um composto.
BRPI0512252A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
DK1968571T3 (da) Anvendelse af benzokondenserede heterocykliske sulfamidderivater som neuroprotektive midler
DK1973539T3 (da) Anvendelse af benzokondenserede heterocykliske sulfamidderivater til behandling af depression
EA200870086A1 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства
BR122018070508B8 (pt) derivados de arilamida triazol-substituída e seu uso
DE59802356D1 (de) Lagerstabile ophthalmische zusammensetzungen, umfassend diclofenac und ofloxacin
BR0209930A (pt) Composto, composição farmacêutica, método para tratar doenças proliferativas, e, uso de um composto
BRPI0409763A (pt) compostos de arila como moduladores de ppars, método de modulação, método de inibição da formação de adipócitos em um mamìfero, método de tratamento de uma doença ou uma condição modulada por ppar e composição farmacêutica
AR020660A1 (es) Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
BR0308162A (pt) Derivados de indolil-uréia de tienopiridinas úteis como agentes antiangiogênicos e métodos para o seu uso

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2156 DE 02/05/2012.